Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrin
- Development stage
- Unknown
- Lead developer
- Kafrelsheikh University
- Modality
- Small Molecules
01
Overview
**5,10,15,20-Tetrakis(4-sulfonatophenyl)porphyrin** is a water-soluble synthetic sulfonated porphyrin photosensitizer, also called TPPS. Kafrelsheikh University registered it as an investigational intervention, described as sulfonatoporphyrin plus sunlight exposure, in the Phase 1 COVID-19 study NCT04371822. The proposed therapeutic rationale was light-driven photodynamic generation of reactive oxygen species to damage viral structures; this was a hypothesis in the study rationale and should not be interpreted as established clinical efficacy against COVID-19. ([deltatrials.com](https://deltatrials.com/trial/NCT04371822))\n\nTPPS is a defined porphyrin chemical substance with CAS number 35218-75-8; it has also been studied as a photosensitizer and as an experimental contrast-media-related compound, but the Kafrelsheikh program was registered as a therapeutic COVID-19 investigation rather than a diagnostic-imaging product. ([pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/compound/tpps4))
- Other names
- 4,4',4'',4'''-(21H,23H-porphine-5,10,15,20-tetrayl)tetrakis(benzenesulfonic acid)meso-tetra(4-sulfonatophenyl)porphineSulfonatoporphyrintetraphenylporphine sulfonatetetraphenylporphyrin tetrasulfonic acidTPPSTPPS4TPPS-4TPPS 4
Beyond the preview
Go deeper on 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrin.